A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer

Cotto, Candace; Bérille, J.; Souquet, Pierre-Jean; Riou, R; Croisile, Bernard; Turjman, Francis; Giroux, B.; Brune, J; Trillet‐Lenoir, Véronique

doi:10.1016/0959-8049(95)00507-2

Cited by 40 publications

(19 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Riviere et al considered the combination of CDDP and FTM and observed 38% and 23% of RRs on BMs and extracranial disease, respectively, with a favorable toxicity profile [9]. Cotto et al considered the same combination in 31 NSCLC patients with BMs which was associated with a median duration of response of 20.5 weeks (28.5 weeks for responders versus 16 weeks for non-responders) [10]. Nevertheless, this study registered an elevated myelotoxicity probably due to the higher dose of CDDP employed with respect to the previous study.…”

Section: Introductionmentioning

confidence: 97%

Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: A multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603)

et al. 2011

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 97%

Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: A multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603)

et al. 2011

View full text Add to dashboard Cite

“…Patients who were administered chemotherapy alone had an intracranial response rate of 27%, with no difference in median or 6-month survival rates. Cotto et al [18] and Minotti et al [19] reported 16% and 35% (4 and 5.3 months, median survival time) radiation response rates in patients with CNS metastases, respectively, with evidence of intracranial response. Lee et al [20] described an experience with 30 patients who were treated at MD Anderson (Houston, TX) with carboplatin and paclitaxel.…”

Section: Chemotherapymentioning

confidence: 97%

Treatment options for brain metastases in patients with non-small cell lung cancer

Taimur

Edelman

2003

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Brain metastases are a common complication for patients with non-small cell lung cancer and a significant cause of morbidity and mortality. In the past, treatment of brain metastases and lung cancer focused on symptom palliation with whole brain radiotherapy (WBRT) and steroids because of the grim outlook for patients. However, recent advances in technology and surgical techniques have created more options for the management of brain metastases, which include surgery, irradiation, stereotactic radiosurgery, and chemotherapy. These aggressive approaches have resulted in an improvement of neurologic outcomes and survival rates of patients with non-small cell lung cancer. Central nervous system (CNS) metastases can be divided into three groups: solitary CNS metastases with controlled or controllable primary disease, oligometastatic disease (fewer than three metastases), and multiple metastases. For patients with solitary CNS metastases, long-term survival is possible. A radical treatment approach involving surgical resection or radiosurgery, followed by WBRT, is recommended. For patients with oligometastatic disease, surgical resection or radiosurgery is considered in selected cases and WBRT is indicated. For patients with multiple metastases, WBRT is recommended. For patients with oligometastatic disease and patients with multiple metastases, recent evidence indicates that systemically effective chemotherapy may produce responses and can be instituted safely before radiotherapy. The treatment timing of chemotherapy and radiotherapy should be individualized.

show abstract

“…(Table 1) Many chemotherapeutic regimens have been tested in phase II or III trials for the treatment of brain metastases arising from NSCLC. There are 8 larger reports (15)(16)(17)(18)(19)(20)(21)(22) with more than 10 patients, published from 1994 to 2008 in English, on front-line chemotherapy of brain metastases from NSCLC. In patients with NSCLC, 17-50% of patients with previously untreated brain metastases responded to a combination of cisplatin plus fotemustine; carboplatin plus etoposide; cisplatin plus teniposide; cisplatin plus etoposide; cisplatin plus ifosfamide, CPT-11; cisplatin plus vinorelbine; carboplatin plus vinorelbine, gemcitabine; cisplatin plus paclitaxel.…”

Section: Non-small Cell Lung Cancer (Nsclc)mentioning

confidence: 99%

Medical Management of Brain Metastases from Lung Cancer

Yamanaka¹

2011

Brain Tumors - Current and Emerging Therapeutic Strategies

View full text Add to dashboard Cite

A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer

Cited by 40 publications

References 9 publications

Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: A multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603)

Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: A multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603)

Treatment options for brain metastases in patients with non-small cell lung cancer

Medical Management of Brain Metastases from Lung Cancer

Contact Info

Product

Resources

About